



PHILIPS

Forming the foundations of your cardio-oncology care pathway

Supporting cardiovascular prevention workflows in line with the 2022 ESC Guidelines on cardio-oncology

Cancer therapy-related cardiovascular toxicity monitoring and prevention strategies demand a truly interdisciplinary effort, as cardiologists must collaborate closely with oncology, hematology and other departments.

At Philips, we are ready to support multidisciplinary cardio-oncology teams in combining disciplines and practice, with our end-to-end echocardiography workflow suite.

Our AI-driven tools allow for a comprehensive baseline assessment, giving a robust foundation to risk stratification and monitoring strategies. And our powerful workflow solutions provide multidisciplinary cardio-oncology teams with a patient-centric overview that yields clear insights into the status of every patient during their cardio-oncology journey.

Supporting cardiologists in enhancing survivorship

To help avert cardiotoxicity, prevention is the key – by identifying potential at-risk patients through comprehensive baseline stratification, as well as by monitoring cancer patients as they receive their treatment, thereby detecting potential biomarkers that could indicate the early stages of myocardial damage or cardiac dysfunction.

These priorities are reflected by the recently published European Society of Cardiology (ESC) guidelines for cardio-oncology, which are available to view [here](#).¹

At Philips, we seek to help multidisciplinary cardio-oncology teams to facilitate cancer treatment, improving the potential for enhanced patient outcomes.

Connect the dots

Empower multidisciplinary cardio-oncology teams to access patient data from anywhere in a single longitudinal view – from ECG, blood pressure and biomarker data to high-quality images

Determine stratification and frequency of treatment – monitor, progress and follow-up

Follow a standardized, reproducible scan protocol no matter which clinician or platform is involved – building strong foundations for defining each patient's treatment plan



Define robust cardiovascular toxicity risk scores

Take a highly standardized, easy-to-follow approach to cardio-oncology care and cardiotoxicity risk management – with solid baseline risk predictors

Perform baseline assessment

Work with AI-driven tools to capture superb images and solid, robust quantification – and integrate results from other modalities (e.g. MR) if further clarity is needed

Helping cardiologists meet their clinical and workflow challenges

Working in line with the 2022 ESC Guidelines on cardio-oncology

Our solutions – including the Philips EPIQ CVx and Affiniti CVx cardiac ultrasound systems, together with Ultrasound Workspace and Cardiovascular Workspace, plus our range of cardiac MR solutions and capabilities – pave the way for robust, reproducible measurements and a clearly defined cancer treatment monitoring pathway for every patient, while helping clinical teams manage increased patient volumes efficiently.

These solutions help multidisciplinary cardio-oncology teams to manage the patient journey and coordinate at every step, through diagnosis to treatment and follow-up.

Our cardio-oncology solutions and capabilities at a glance



Cardiac imaging systems

Philips EPIQ CVx and Affiniti CVx

Our cardiology ultrasound systems deliver exceptional imaging, high exam efficiency and robust, reliable quantification capabilities. Quickly and easily acquire high-quality, standard 2D imaging, complemented by AI-driven 3D imaging, for a consistently strong baseline assessment.

Philips Ingenia Ambition 1.5 T

Cardiac MRI (CMR) is increasing in prominence across international cardiology and oncology guidelines and has broad applications in cardio-oncology². The Philips Ingenia Ambition 1.5T ensures high-quality scanning and reliable performance and patient-centered productivity. Its fully sealed magnet with only seven liters of liquid helium (instead of the usual 1,500 liters) is a safeguard against the consequences of helium scarcity and enables easy siting.

Philips Advanced Visualization

MR Cardiac Suite is part of Advanced Visualization Workspace and is a scalable solution that allows performing comprehensive cardiac assessment based on cardiac MR studies. The suite includes cardiac function analysis (LV&RV), cardiac late enhancement assessment, myocardial T1 and T2 mapping, and more, which allow a comprehensive view of cardio-oncology patients. The suite features a seamless user experience and automated, customizable workflows that aid physicians in reading these complex cases.



Workflow solutions

Philips Cardiovascular Workspace³

This scalable, interoperable image and information management solution allows cardiology teams to gather all patient information in a single place, ranging from ECG, blood pressure and biomarker data to acquired images. This information is presented in a longitudinal, patient-centric view, within an easy-to-access tool that can be used from anywhere to support and enable the multidisciplinary cardio-oncology teams.

Philips Ultrasound Workspace

Ultrasound Workspace is a holistic, scalable cardiovascular viewing, analysis and reporting system. It provides high levels of AI-powered automation to increase reproducibility and enhance diagnostic confidence to manage and support cardio-oncology patients.



Features and capabilities

AutoStrain

One-button, automated measurements of global longitudinal strain (GLS) – providing robust, reproducible strain measurement.

Dynamic HeartModel^{AI}

AI-driven measurements of 3D ejection fraction (3DEF) in seconds as part of a routine workflow, for enhanced cardiac function assessments.

iRotate

Intelligent rotation that keeps the transducer in a fixed position, facilitating reproducible, robust images and helping bridge the gap between 2D and 3D thinking.

Fast-SENC and MyoStrain*

With the combination of Philips Fast-SENC and MyoStrain* early dysfunction of heart can be detected across 48 segments with a 12-heartbeat MRI scan* which helps to prevent and manage heart failure.

Together, Philips solutions and capabilities deliver efficient and flexible workflows today, while empowering multidisciplinary cardio-oncology teams to accommodate the increased patient volumes of tomorrow.

To learn more about solutions and services that can support you in managing your cardio-oncology care pathways, please visit our website at www.philips.com/cardiotoxicity.

To view the ESC Guidelines for patients, visit: www.escardio.org/Guidelines/guidelines-for-patients

¹ Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., Cutter, D. J., De Azambuja, E., De Boer, R. A., Dent, S. F., Farmakis, D., Gevaert, S. A., Gorog, D. A., Herrmann, J., Lenihan, D., ... Srojinidova, N. (2022). 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). *European Heart Journal*, 43(41), 4229–4361. <https://doi.org/10.1093/eurheartj/ehac244>

² *European Heart Journal - Cardiovascular Imaging*, Volume 22, Issue 4, April 2021 pages 383-396.

³ Philips Cardiovascular Workspace is the commercial name of the medical device Philips IntelliSpace Cardiovascular.

* Copyright Myocardial Solutions, Inc. 2021. All rights reserved.

